Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment market to reach USD 3.66 Bn in 2020

MRSA infection is highly contagious and can spread through person-to-person contact or a surface or object touched by MRSA-infected person. If MRSA is contracted in nursing homes or hospitals, it is through contaminated hands, direct contact with the undressed wound, poorly sanitized surgical instruments, or contaminated linens. This hospital-acquired MRSA (HA-MRSA) could further cause pneumonia and blood infections. Outside of healthcare settings, the infection is known as community-acquired MRSA (CA-MRSA).

Get | Download Sample Copy with Graphs & List of Figures:
https://www.futuremarketinsights.com/reports/sample/rep-gb-10406

Those who undergo hemodialysis on regular basis are at the highest risk of contracting HA-MRSA. Further, those staying in nursing homes and the ones who had been hospitalized are also at risk.

On the other hand, CA-MRSA prevalence is higher among individuals involved in contact sports, the ones living in unhygienic conditions, and those working in day care centers.

Oral Antibiotics Remain the First Treatment Option for MRSA Infection Treatment

Oral antibiotics are administered to MRSA-infected patients as the first course of action. Vancomycin is one such antibiotic recommended by IDSA (Infectious Disease Society of America).

With increasing incidences of MRSA across the globe (with the U.S., Canada, Japan, and Indonesia having the highest rates as per the WHO), the demand for the above-mentioned oral antibiotic is likely to increase manifold, thereby boosting the MRSA treatment market.

For More Information or Query or Customization Before Buying, Visit:
https://www.futuremarketinsights.com/customization-available/rep-gb-10406

Covid-19 Crisis Impact – Significant Rise in Secondary MRSA Infections to Catalyze the Market

The outbreak of Covid-19 has increased the risk of secondary infections. Covid-19 positive individuals are reported to be more vulnerable to MRSA infections.

According to Centers for Disease Control (CDC) 1 in 7 Covid-19 hospitalized patients have contracted secondary bacterial infections, and the infection has proven to be fatal in 50% of these patients.

These factors are likely to raise short-term demand for first-line antibiotic treatment against secondary MRSA infections in Covid-19 patients.

MRSA Treatment Market Moderately Consolidated with a Few Specialized Industry Players

The key players are on the “innovation” spree to consolidate their market share. Everyone – right from top tier innovator companies to small size developer companies are looking out for differentiators in this regard. The top-notch players are going for production of new antibiotics, acquisition, and exclusive product licensing to mitigate the entry of small and new companies. The other strategies followed are “exclusive distribution” and “development collaborations”.

Although advanced MRSA treatments have sprung up all over the globe, most of the leading manufacturers are U.S.-based.

Ask Us Your Questions About This Report:
https://www.futuremarketinsights.com/ask-question/rep-gb-10406

Pfizer Inc. alone owns a significant share of the U.S. market, but the marketplace is rapidly becoming competitive owing to gains made by players such as Melinta Therapeutics, Inc. The company received FDA approval for Baxdela (delafloxacin) for extended indication in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria).

In January 2018, Cutis Pharma Inc., a US based specialty pharmaceutical company, obtained approval for its Firvanq (vancomycin hydrochloride) oral solution for gastrointestinal infection of MRSA.